Development asset linked to CSPC Pharmaceutical Group in public FDA and regional records.
biotech · Colorectal Liver Metastases
CSPC Pharmaceutical Group
CSPC Baike (Shandong) Biopharmaceutical Co.,
CSPC Pharmaceutical Group drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
419 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Employees
- 419
- Programs
- 1
- Drugs
- 2
- Patents
- 0
CSPC Pharmaceutical Group pipeline
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
CSPC Pharmaceutical Group drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
paclitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor